Overexpression of AMP-activated kinase sensitizes Sorafenib-resistant Hepatocellular cancer cells and decreases stem cell markers

Data used to generate figures of the paper by Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I. “Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib” Mol Oncol. 2019 May;13(5):1311-1331. doi: 10.1002/1878-0261.12488. In this study we demonstrate that the AMP-activated kinase AMPK reverse the Cancer Stem cell features of Hepatocellular CSC.本数据集用于生成Bort A、Sánchez BG、Mateos-Gómez PA、Vara-Ciruelos D、Rodríguez-Henche N、Díaz-Laviada I所发表论文的配图，该论文题为《靶向腺苷酸活化蛋白激酶（AMP-activated kinase）可影响索拉非尼（sorafenib）长期治疗诱导的肝细胞癌干细胞》，刊载于《分子肿瘤学（Mol Oncol）》2019年5月，第13卷第5期，页码范围1311-1331，DOI：10.1002/1878-0261.12488。本研究证实，腺苷酸活化蛋白激酶（AMP-activated kinase, AMPK）可逆转肝细胞癌干细胞（hepatocellular cancer stem cells, CSC）的肿瘤干细胞特性。